Vivus VVUS
-
Orbimed's $3.4B Filing: 2 Stocks It And Other Healthcare Funds Bought In Q1, And Other Trades
By Ganaxi Small Cap Movers : New York-based Orbimed Advisors is the world's largest healthcare investment firm, with over $5 billion in assets under management, including $3.37 billion in 13-F assets per its most recent Q1 2012 filing , up from $3.05 billion in the prior quarter Complete Story »
-
Hitting The Jackpot With Small-Cap Bio Pharma Investment, Part 3: The Immune System
By Scott Matusow : In the final part of my three part series on "Hitting The Jackpot With Small Cap Bio Pharma Investment," I shift the focus to the what looks like the future of cancer treatment therapy. What if cancer could be arrested, forced into remission, and even cured by simply manipulating
-
5 Biotechnology Stocks With Upcoming Catalysts
By Helix Investment Management : Of all the sectors in the stock market, no sector moves more due to corporate developments than the biotechnology sector. A single drug trial or FDA decision can send stocks soaring, or plunging. Due to this trend, many investors choose to trade biotechnology stocks
-
Arena - What Now?
By Mina Shaker : In case you have been sleeping under a rock, Arena Pharmaceutical's ( ARNA ) weight loss drug, Lorcaserin, was approved by an advisory board on Thursday afternoon. Friday, the stock sky rocketed up over 90 percent and closed up over 75 percent in the green, but the fun is just ...
-
9 Rallying Biotech Stocks Being Snapped Up By Hedge Funds
By Kapitall : Interested in the growth prospects of the biotech industry? For a closer look at stocks of the biotech sector with positive market sentiment, we ran a screen. We began by screening the biotech industry for stocks currently rallying above their 20-day, 50-day, and 200-day moving ...
-
Arena Pharmaceutical's Recent Spike Offers Income Opportunity
By John Mylant : Arena Pharmaceuticals ( ARNA ) shot up 73.4% Friday anticipating the FDA Advisory Committee's vote in favor of Lorcaserin's benefit / risk profile for weight management. (click to enlarge) The potential profits for Arena Pharmaceuticals are incredible considering an estimated ...
-
6 Mid-Cap Biotechnology Stocks With Great Liquidity And Rated Buy Or Better
By ZetaKap : Are you looking for mid-sized companies that still have room to grow? Are you interested in gaining exposure to biotechnology companies and companies with high liquidity? Do you prefer stocks that analysts rate as 'Buy', or better? If so, here are some ideas to start your stock search.
-
Arena Pharmaceuticals: FDA Approval Is Just The Beginning
By Osman Gulseven : Several important data points were released in the past week. The stocks started the week with a mixed investor sentiment. However, they ended mostly in the negative territory. While basic materials were the biggest losers, healthcare stocks ended the week with modest gains ...
-
Hitting The Jackpot With Small Cap Bio Pharma Investment, Part 1
… receive approval from the FDA next month and actually beat Vivus 's ( VVUS ) weight loss drug Qnexa to the punch and become the first FDA approved weight loss drug since 1999. Vivus investors know what it is like to hit Complete Story …
-
Arena's Weight Loss Drug Receives FDA Advisory Panel Recommendation For Approval
By Scott Matusow : Today, an FDA advisory panel voted 18-4 to recommend approval of lorcaserin, developed by Arena Pharma ( ARNA ) . The panel concluded that its benefits "outweigh the potential risks when used long term" in overweight and obese people. One panel member abstained from voting. There